Research in the News: Arming the Immune System to Fight Myeloma

A potentially disease-modifying therapy for osteoarthritis has reached a key milestone now that a U.S. patent has been issued for FX201, a gene-therapy product candidate based on work led by Baylor College of Medicine researchers.

Researchers at ETH Zurich have discovered redundancies in the biochemical signalling pathways of immune cells. This finding has important implications for advances in cancer immunotherapy, among other areas.

The identification of molecular signatures that reflect the pathology of lupus and arthritis provide new insights into tissue damage, and set the stage for uncovering potential drug target candidates.